These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 34156606

  • 1. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL, Patnaik P, Hartmann N, Bohn RL, Garry EM, Wallace L.
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [Abstract] [Full Text] [Related]

  • 2. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D, Bengtson LGS, Conoscenti CS, Laouri M, Shetty SS, Anderson AJ, Brown KK.
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [Abstract] [Full Text] [Related]

  • 3. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
    Olson AL, Hartmann N, Patnaik P, Garry EM, Bohn RL, Singer D, Baldwin M, Wallace L.
    Adv Ther; 2022 Apr; 39(4):1794-1809. PubMed ID: 35199282
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.
    Nili M, Steffens A, Anderson A, Brekke L, Grace Johnson M, Veeranki P, Olson AL.
    J Manag Care Spec Pharm; 2024 Feb 03; 30(2):163-174. PubMed ID: 38308627
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN.
    Drugs; 2021 Apr 03; 81(5):575-586. PubMed ID: 33765296
    [Abstract] [Full Text] [Related]

  • 10. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).
    Nasser M, Larrieu S, Boussel L, Si-Mohamed S, Bazin F, Marque S, Massol J, Thivolet-Bejui F, Chalabreysse L, Maucort-Boulch D, Hachulla E, Jouneau S, Le Lay K, Cottin V.
    Respir Res; 2021 May 24; 22(1):162. PubMed ID: 34030695
    [Abstract] [Full Text] [Related]

  • 11. Burden of illness in progressive fibrosing interstitial lung disease.
    Singer D, Bengtson LGS, Conoscenti CS, Anderson AJ, Brekke L, Shetty SS, Brown KK.
    J Manag Care Spec Pharm; 2022 Aug 24; 28(8):871-880. PubMed ID: 35876293
    [Abstract] [Full Text] [Related]

  • 12. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.
    Lancet Respir Med; 2020 May 24; 8(5):453-460. PubMed ID: 32145830
    [Abstract] [Full Text] [Related]

  • 13. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
    Faverio P, Piluso M, De Giacomi F, Della Zoppa M, Cassandro R, Harari S, Luppi F, Pesci A.
    Respiration; 2020 May 24; 99(10):838-845. PubMed ID: 33264777
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
    Joung KI, Park H, Park S, Shin JY, Kim YH.
    BMC Pulm Med; 2023 Mar 22; 23(1):98. PubMed ID: 36949407
    [Abstract] [Full Text] [Related]

  • 18. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S.
    Mod Rheumatol; 2021 Jan 22; 31(1):13-19. PubMed ID: 32964766
    [Abstract] [Full Text] [Related]

  • 19. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries.
    Hilberg O, Hoffmann-Vold AM, Smith V, Bouros D, Kilpeläinen M, Guiot J, Morais A, Clemente S, Daniil Z, Papakosta D, Fretheim H, Neves S, Alfaro TM, Antoniou KM, Valveny N, Asijee G, Soulard S, Wuyts W.
    ERJ Open Res; 2022 Jan 22; 8(1):. PubMed ID: 35083316
    [Abstract] [Full Text] [Related]

  • 20. Progressive pulmonary fibrosis (PPF): Estimation of incidence and treatment rates in Japan using a claims database.
    Kondoh Y, Ito T, Saito K, Bao H, Sakamoto W.
    Respir Investig; 2024 Jul 22; 62(4):702-709. PubMed ID: 38815414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.